The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Once-Weekly Semaglutide in Adolescents with Obesity
Open accessAbstract
BACKGROUND: A once-weekly, 2.4-mg dose of subcutaneous semaglutide, a glucagon-like peptide-1 receptor agonist, is used to treat obesity in adults, but assessment of the drug in adolescents has been lacking. METHODS: In this double-blind, parallel-group, randomized, placebo-controlled trial, we enrolled adolescents (12 to <18 years of age) with obesity (a body-mass index [BMI] in the 95th percentile or higher) or with overweight (a BMI in the 85th percentile or higher) and at least one weight-related coexisting condition. Participants were randomly assigned in a 2:1 ratio to receive once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo for 68 weeks, plus lifestyle intervention. The primary end point was the percentage change in BMI from baseline to week 68; the secondary confirmatory end point was weight loss of at least 5% at week 68. RESULTS: A total of 201 participants underwent randomization, and 180 (90%) completed treatment. All but one of the participants had obesity. The mean change in BMI from baseline to week 68 was -16.1% with semaglutide and 0.6% with placebo (estimated difference, -16.7 percentage points; 95% confidence interval [CI], -20.3 to -13.2; P<0.001). At week 68, a total of 95 of 131 participants (73%) in the semaglutide group had weight loss of 5% or more, as compared with 11 of 62 participants (18%) in the placebo group (estimated odds ratio, 14.0; 95% CI, 6.3 to 31.0; P<0.001). Reductions in body weight and improvement with respect to cardiometabolic risk factors (waist circumference and levels of glycated hemoglobin, lipids [except high-density lipoprotein cholesterol], and alanine aminotransferase) were greater with semaglutide than with placebo. The incidence of gastrointestinal adverse events was greater with semaglutide than with placebo (62% vs. 42%). Five participants (4%) in the semaglutide group and no participants in the placebo group had cholelithiasis. Serious adverse events were reported in 15 of 133 participants (11%) in the semaglutide group and in 6 of 67 participants (9%) in the placebo group. CONCLUSIONS: Among adolescents with obesity, once-weekly treatment with a 2.4-mg dose of semaglutide plus lifestyle intervention resulted in a greater reduction in BMI than lifestyle intervention alone. (Funded by Novo Nordisk; STEP TEENS ClinicalTrials.gov number, NCT04102189.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Approved by FDA/EMA from age 12.”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [113]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“73% achieved ≥ 5% weight loss and with significant amelioration of CVD factors (e.g. waist circumference, ALT and HbA1c) and no adverse impact on pubertal development and bone health [113].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [113]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Similar efficacy was achieved with once-weekly subcutaneous injections of 2.4 mg semaglutide in the STEP Teens trial among adolescents aged 12–18 years [80]”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [80]
The cited source says what the claim attributes to it.
In the citing paper
“In the STEP TEENS trial, adolescents achieved a − 16.1% mean BMI reduction vs. + 0.6% in the placebo group.”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [113]
In the citing paper
“Similar efficacy was achieved with 2.4 mg once weekly injections in adolescents with comorbidities (STEP Teens) and with a high dose (50 mg once daily) of the oral formulation of semaglutide in adults (OASIS-1) [24, 25].”
From Recent advances in peptide-based therapies for obesity and type 2 diabetes (2024) · cites this paper as [24]
In the citing paper
“However, weight loss was less amongst obese individuals with T2DM (eg 9.6% weight loss with the 2.4 mg once weekly injected semaglutide in STEP-2) for likely reasons described above [17, 24, 25].”
From Recent advances in peptide-based therapies for obesity and type 2 diabetes (2024) · cites this paper as [24]
In the citing paper
“the main trials for which data have been published (STEP 1 through STEP 5, STEP 8, and STEP TEENS) did not include participants who reported having symptoms of major depressive disorder within 2 years before screening, which limits their ability to assess psychiatric adverse events in people with a recent history of depression [3,4,93,94,95,96,97].”
From What Is Food Noise? A Conceptual Model of Food Cue Reactivity (2023) · cites this paper as [97]
In the citing paper
“STEP TEENS studied semaglutide 2.4 mg in adolescents living with obesity and reported that semaglutide versus placebo resulted in a 17.7-kg weight loss over 68 weeks (Table 3B).76”
From Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists (2024) · cites this paper as [76]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Bray, G. A., Kim, K. K., Wilding, J. P. H., & on behalf of the World Obesity Federation (2017) · Obesity Reviews · doi:10.1111/obr.12551 · Cited by 1,612
Overweight in Children and Adolescents
Daniels, S. R., Arnett, D. K., Eckel, R. H., Gidding, S. S., Hayman, L. L., Kumanyika, S., Robinson, T. N., Scott, B. J., Jeor, S. S., & Williams, C. L. (2005) · Circulation · doi:10.1161/01.cir.0000161369.71722.10 · Cited by 1,543
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Self-citationStyne, D. M., Arslanian, S. A., Connor, E. L., Farooqi, I. S., Murad, M. H., Silverstein, J. H., & Yanovski, J. A. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2573 · Cited by 1,375
Self-citationWilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14725 · Cited by 1,128
Posner, K., Oquendo, M. A., Gould, M., Stanley, B., & Davies, M. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1035 · Cited by 1,025
Kelly, A. S., Barlow, S. E., Rao, G., Inge, T. H., Hayman, L. L., Steinberger, J., Urbina, E. M., Ewing, L. J., & Daniels, S. R. (2013) · Circulation · doi:10.1161/cir.0b013e3182a5cfb3 · Cited by 980
Self-citationTwo-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02026-4 · Cited by 868
Cited by
Sorted by citations
Items 601–700 of 794
INOVAÇÕES E DESAFIOS NO TRATAMENTO DA TETRALOGIA DE FALLOT
Silveira, I. M. S., & Escrivães, A. C. N. D. C. (2025) · Jornada Científica do Internato Médico · doi:10.29327/1718890.46-60
Chiconelli, H. M. A., & Desiderati, M. (2025) · Jornada Científica do Internato Médico · doi:10.29327/1718890.46-56
NEUROPROTEÇÃO COM SULFATO DE MANGÉSIO: APLICAÇÃO NA OBSTETRÍCIA
Gouvêa, E. H., & B.Gama, C. R. (2025) · Jornada Científica do Internato Médico · doi:10.29327/1718890.46-53
ATUALIZAÇÕES NOS CRITÉRIOS DIAGNÓSTICOS E TRATAMENTO DA SEPSE.
Cavalcanti, R. D. G., & Perez, M. C. A. (2025) · Jornada Científica do Internato Médico · doi:10.29327/1718890.46-50
HEMORRAGIA DIGESTIVA ALTA POR VARIZES GASTROESOFÁGICAS EM PACIENTES CIRRÓTICOS
Neves, G. V., & Figueiredo, L. F. (2025) · Jornada Científica do Internato Médico · doi:10.29327/1718890.46-54
ANÁLISE DA IMUNIZAÇÃO INFANTIL DE 0 A 5 ANOS EM UM AMBULATÓRIO DE ENSINO
Erthal, S. S., & Rodrigues, S. (2025) · Jornada Científica do Internato Médico · doi:10.29327/1718890.46-32
USO DO OMALIZUMABE PARA O TRATAMENTO DA ASMA ALÉRGICA GRAVE
Fernandes, G. N., & Nunes, C. P. (2025) · Jornada Científica do Internato Médico · doi:10.29327/1718890.46-34
TRANSTORNOS DA PERSONALIDADE DO GRUPO B NA ATENÇÃO PRIMÁRIA
Peclat, B. E., & Dóczy, A. D. P. (2025) · Jornada Científica do Internato Médico · doi:10.29327/1718890.46-35
DeLacey, S. E., Dieguez, A. C., & Bensignor, M. O. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01823-7
Kim, R., & Benden, E. (2025) · Springer eBooks · doi:10.1007/978-3-031-97759-6_37
SKALE Kids Trial: liraglutide efficace nell’obesità anche nei bambini: l’effetto è bello finché dura
Arosio, E., Brusadelli, C., & Cazzaniga, R. (2025) · QUADERNI ACP · doi:10.53141/peqacp.2025.1.n1
Continuity of care in obesity clinical care
Lesmes, I. B., García, J. M. F., Vilarrasa, N., Arroyo, V. R., de Hollanda, A., Cortés, G. B., & Ballesteros-Pomar, M. D. (2025) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2025.501658
Pediatric metabolic and bariatric surgery: When is the right time to operate?
Shacker, M., Chinn, J. O., Pratt, J. S. A., & Fell, G. L. (2025) · Current problems in pediatric and adolescent health care · doi:10.1016/j.cppeds.2025.101882
de Ferranti, S. D., Teng, J. E., Arslanian, S. A., Atz, A. M., Brothers, J. A., Cartoski, M. J., Freemon, D., Magge, S. N., Mahle, W. T., Mietus‐Snyder, M., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.107327
Self-citationCampbell, M., Lenzen, C., Maginot, T. R., & Kumar, M. M. (2025) · BMJ Case Reports · doi:10.1136/bcr-2025-269199
Eisa, N., & Barood, O. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.11.018 · Cited by 1
Koehlmoos, T. P., Madsen, C., Banaag, A. L., & Adirim, T. A. (2024) · Figshare · doi:10.6084/m9.figshare.26612507
Koehlmoos, T. P., Madsen, C., Banaag, A. L., & Adirim, T. A. (2024) · Figshare · doi:10.6084/m9.figshare.26612501
Sessler, T. M., Beier, J. P., Villwock, S., Jonigk, D., Dahl, E., & Ruhl, T. (2024) · Figshare · doi:10.6084/m9.figshare.26943930
Koehlmoos, T. P., Madsen, C., Banaag, A. L., & Adirim, T. A. (2024) · Figshare · doi:10.6084/m9.figshare.26612510
Koehlmoos, T. P., Madsen, C., Banaag, A. L., & Adirim, T. A. (2024) · Figshare · doi:10.6084/m9.figshare.26612504
Lerner, J. J., Schmid, L., Zorn, S., von Schnurbein, J., Siebert, R., & Wabitsch, M. (2025) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2606-2353
Continuidad asistencial en la atención clínica de la obesidad
Bretón, I., García, J. M. F., Vilarrasa, N., Arroyo, V. R., de Hollanda, A., Cortés, G. B., & Ballesteros-Pomar, M. D. (2025) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2025.501658
Chen, P., Tsai, S.-M., Chang, C.-H., Yang, H.-R., Huang, Y.-J., Liu, H. C., Chang, K., & Chen, H.-L. (2026) · Korean Journal of Pediatrics · doi:10.3345/cep.2025.01774
Preventing Excess Fat Mass Gain in Severe Pediatric Obesity
Wabitsch, M., Brandt-Heunemann, S., Ulrich, K., & Zorn, S. (2025) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2025.5145
Anti-obesity Pharmacotherapy for Patients with Genetic Obesity Disorders
Welling, M. S., van Rossum, E. F. C., & van den Akker, E. (2025) · Springer eBooks · doi:10.1007/978-3-032-04095-4_15
Treatment Approaches for Obesity in Children With Heterozygous MC4R Variants
Salama, M., Saba, L., Valdez, L., Lteif, A. N., & Kumar, S. (2026) · Clinical Obesity · doi:10.1111/cob.70069
Perceptions of GLP-1 RA Use for Children With Obesity Among Caregivers With Food Insecurity
Stephenson, K. M., Schwartz, N. R. M., Person, H., Blondet, N. M., Benitez-Cortez, M., Nuding, M. E., Kraft, S. A., & Suskind, D. L. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.52825
Savira, N. F., Bambang, P., & Atika, A. (2025) · International Journal Of Scientific Advances · doi:10.51542/ijscia.v6i6.39
Łuczak, P. M., Perediatkiewicz, J., Liszka, P., Puchalski, K., Patrzykąt, K. M., Olejnik-Chlewicka, K. M., Urbański, W., Zasiadła, M., Brodowski, J., & Ogorek, A. (2026) · Cureus · doi:10.7759/cureus.101545
Uçak, A., Pazarcıkcı, F., & Çatal, A. T. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08486-8
Szelka, H., Czyżykowski, K., Gęsińska, A. M., Golis, B., Edyko, P., Babula, A., Golus, W., Andrzejewska, K., Przybyła, Z., & Woźniak, H. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4323
Beyond lifestyle modification: the role of GLP-1 receptor agonists in treating pediatric obesity
Wen, H. (2026) · Frontiers in Pediatrics · doi:10.3389/fped.2025.1684485
Gupta, S., Lal, P., Gupta, A., & Chaudhary, B. R. (2026) · Korean Journal of Pediatrics · doi:10.3345/cep.2025.02838
Filho, D. W. D., Lima, S. R., Lopes, L. R. D. P., Silva, J. V. J. F., Avellar, G. S., Sanches, M. V. P. T., Silva, V. C., Silva, V. C., & da Fonseca, T. L. (2026) · Contribuciones a las Ciencias Sociales · doi:10.55905/revconv.19n.1-247
merging Advances in Oral and Injectable Anti-Obesity Pharmacotherapies: A Review of Current Evidence
Madsbad, S. (2025) · Medical Research Archives · doi:10.18103/mra.v14i1.7208
Tou, A. M., & Panganiban, J. A. (2026) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2026.115011
Filho, D. W. D., Lima, S. R., Lopes, L. R. D. P., Silva, J. V. J. F., Avellar, G. S., Sanches, M. V. P. T., Silva, V. C., & da Fonseca, T. L. (2026) · Artefactum · doi:10.23900/artefactum.v25i1.2507
Ready for the challenge: navigating the evolving landscape of GLP-1s for pediatric obesity treatment
Burton, E. T., Ramos-Velez, C. M., McKelvey, N. J., Estrada, E., Parks, E. P., & Eddington, A. R. (2026) · Journal of Pediatric Psychology · doi:10.1093/jpepsy/jsag002
Prioritising nutrition alongside paediatric obesity management medications
Ruggiero, C. F., Spreckley, M., Davis, N. L., & Brown, A. C. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00008-2
Diaz, M. E. C., Kim, G., & Vakharia, M. (2026) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2026.156317
Qiao, X., Xie, T., Zhang, Y., Sun, C., Wu, X., Chen, Y., Yao, Q., Shi, H., Li, S., Zhao, H., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69793-3 · Cited by 1
Medikamentöse Therapie der Adipositas
Malzner, A. (2026) · Journal für Gastroenterologische und Hepatologische Erkrankungen · doi:10.1007/s41971-026-00250-0
Pediatric Obesity Treatment: From Paradigm Shift to Implementation Challenges
Chamarthi, V. S., & Nadler, E. P. (2026) · Clinical Pediatrics · doi:10.1177/00099228261426666
Disparities in Medication Treatment of Type 2 Diabetes and Obesity
Whooten, R., Allen, L., & Stanford, F. C. (2026) · PEDIATRICS · doi:10.1542/peds.2025-074840
Pharmacotherapy in childhood obesity: Key points from the 2023 AAP clinical practice guideline
Alam, F., & Newbern, D. (2026) · Seminars in Pediatric Surgery · doi:10.1016/j.sempedsurg.2026.151608
Current updates and anesthetic considerations for adolescent metabolic and bariatric surgery
Doyle, N. M., Weisberg, E. L., Glenski, T. A., & Taylor, C. M. (2026) · Seminars in Pediatric Surgery · doi:10.1016/j.sempedsurg.2026.151610
BEYOND THE SCALE: COMPREHENSIVE TREATMENT OPTIONS FOR YOUTH OBESITY
Jabłonowska, M., & Grzeszczuk, P. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4236
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Pediatric Obesity
KURAN, Ö., & Cömert, T. K. (2026) · Current Treatment Options in Pediatrics · doi:10.1007/s40746-026-00370-y
Fiore, G., Altayeva, A., Panelli, S., Zan, D. D., Sterzi, L., Calcaterra, Tosi, M., Folli, F. B., Zuccotti, G., Comandatore, F., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02860-0
Nueva era terapéutica en la obesidad infantojuvenil: oportunidades y retos de futuro
Molina-Giraldo, P., Suárez-Ortega, L., & Ramon‐Krauel, M. (2026) · Anales de Pediatría · doi:10.1016/j.anpedi.2026.504194
Semaglutide for obesity: a pill for every ill?
Puntis, J. W. L. (2026) · Archives of Disease in Childhood · doi:10.1136/archdischild-2025-330170
Treatment of Youth‐Onset Type 2 Diabetes: Focus on SGLT‐2 Inhibitor Use
Arslanian, S. A., Barrett, T. G., & Shehadeh, N. (2026) · Pediatric Diabetes · doi:10.1155/pedi/4555805
Self-citationNove mogućnosti liječenja pretilosti
Šabašov, I. U. (2026) · Paediatria Croatica · doi:10.13112/pc.1168
Silva, E. A. S., da Costa, G. S., de Oliveira, T. B., & da Conceição, M. S. (2026) · Pensar Acadêmico · doi:10.21576/pensaracadmico.2026v24i1.4526
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · International Journal of Cardiovascular Sciences · doi:10.36660/ijcs.20260056
Prevalence and Predictors of Guideline Concordant Pediatric Obesity Care: A Narrative Review
Orr, C. J., Streetman, A. E., Carruyo, I. A., Beck, A. L., Queen, K., Sanders, T., & Heerman, W. J. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00712-9
Vijay Kumar, K. V., Kshirsagar, P., Mishra, M., & Panwar, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70761
International consensus on adolescent metabolic health: prevention of obesity and type 2 diabetes
Shaltout, I., Schwarz, P. E. H., Meligi, A. A. H. E., Sherif, I. E., Hammad, H., Abdelghaffar, S., Hegazy, M., Nasr, G. M., Habeeb, H., Barakat, E., et al. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02142-y · Cited by 1
Hayes, E., Nillsen, A., Rowe, P. W., Siafarikas, A., & Abraham, M. B. (2026) · Hormone Research in Paediatrics · doi:10.1159/000552014
Semaglutide for obesity management: A narrative review of efficacy, safety, and future directions
Hajibandeh, S., Tao, Y.-A., Hsieh, M.-H., Liu, H.-H. “., Cheng, Y.-F., Lee, K.-H., Hsieh, S.-Y., & Lu, C. (2026) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2026.103117
Pestka, J., Figiel, A., Zaborek, P., Bernad, M., Widomska, K., & Marguła, R. (2026) · Quality in Sport · doi:10.12775/qs.2026.54.70610
Clement, M. A., & Samuel, J. P. (2026) · Pediatric Nephrology · doi:10.1007/s00467-026-07293-8
Ilyas, A. (2026) · Premier journal of public health. · doi:10.70389/pjph.100026
Zagórska, A., Kotowicz, M., Zielińska, M., Szajewski, P., Ciećwierz, J., Koczkodaj, M., & Bieniak-Pentchev, M. (2026) · Annales Academiae Medicae Silesiensis · doi:10.18794/aams/214724
Non-Pharmacological and Integrated Therapy of Diabetes Mellitus: A Narrative Review
Cavezzi, A., Cameli, S., Donzelli, G., Colucci, R., & Cavezzi, S. (2026) · Journal of Theoretical and Applied Vascular Research · doi:10.24019/jtavr.252
Barbosa, P. E. T., Pezzi, S. A., & de Santana, E. S. (2026) · Veredas do Direito Direito Ambiental e Desenvolvimento Sustentável · doi:10.18623/rvd.v23.6237
GLP-1 Receptor Agonists in Pediatric Obesity: Evidence, Knowledge Gaps, and Clinical Implications
Abramowicz, A. D., Rumin, M., Gosztyła, D., МУЗЫКА, Н., Kość, K., Panek, G., Bukwald, W., Giersz, J., Prusek, A., & Piliński, R. (2026) · Archiv Euromedica · doi:10.35630/2026/16/iss.2.8
Disseminating and Implementing the Science of Pediatric Obesity Treatment and Prevention
Staiano, A. E., Estabrooks, P. A., Buccini, G., Cook, S. R., Davis, A. M., Davison, K. K., Fiechtner, L. G., Heerman, W. J., Hill, J. L., Inge, T. H., et al. (2026) · Obesity · doi:10.1002/oby.70197
Self-citationFerrarese, A., Cananzi, M., Bosa, L., Senzolo, M., Germani, G., Vivian, L. M., Mescoli, C., Dolcet, A., Gringeri, E., D’Antiga, L., et al. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.v32.i18.116902
Current perspectives on the management of hypertension in children and adolescents
Jayasekara, N., & Shenoy, M. (2026) · Paediatrics and Child Health · doi:10.1016/j.paed.2026.04.001
Kaufman, R. C. (2026) · Research Square · doi:10.21203/rs.3.rs-9657897/v1
Pharmacological interventions for the treatment of obesity in children and adolescents
Gerardi, C., Allocati, E., Prutsky, G. J., Carrano, F. M., Romano, E., Giorgi, S. D., Metzendorf, M., Calcaterra, V., Lorenzo, N. D., & Banzi, R. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015986
AVALIAÇÃO COMPARATIVA DOS EFEITOS ADVERSOS DE TERAPIAS INJETÁVEIS PARA CONTROLE DO PESO CORPORAL
Sousa, M. E. D. D., & Caetano, R. C. D. P. E. S. (2026) · LUMEN ET VIRTUS · doi:10.56238/levv17n60-033
Adipositas und Diabetes mellitus Typ 2 (Update 2026)
Brix, J. M., Clodi, M., Harreiter, J., Hoppichler, F., Fw, K., Itariu, B.-K., Parzer, V., Resl, M., Schindler, K., Toplak, H., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-026-02706-y
Clinical Trial Design Considerations to Improve Equitable Anti-Obesity Medication Access for Youth
Moore, J. M., & Kelsey, M. M. (2026) · Diabetes Care · doi:10.2337/dci25-0129
The Management of Polycystic Ovary Syndrome in Adolescents with Obesity
Barber, T. M., Thadani, P., Niven, E. V., Kyrou, I., & Randeva, H. S. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03639-8
Soliman, A. T., Alyafei, F., Alaaraj, N., Mohamed, S., Hamed, N., & Elsiddig, S. A. (2026) · Jurnal Gastrohepatologi Anak Indonesia/Archives of Pediatric Gastroenterology, Hepatology, and Nutrition · doi:10.58427/apghn.5.2.2026.106-120
Lischka, J., Torbahn, G., Vallis, M., Mörwald, K., Gomahr, J., Forslund, A., Stenlid, R., Manell, H., Bergsten, P., Geiersberger, S., et al. (2026) · Pediatric Obesity · doi:10.1111/ijpo.70122
Self-citationCurrent and forthcoming pharmacotherapies for adolescent obesity: Evidence-based review
Fuentes‐Mendoza, J. M., Concepción‐Zavaleta, M. J., Dueñas, L. G. D., Jara-Pianto, J. M. J., Sierra-Martel, J. A., Medina-Angulo, C. A., Flores, H. M. V., Mendoza-Godoy, J. J., Zavaleta‐Gutiérrez, F. E., & Paz‐Ibarra, J. (2026) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.118730
Equitani, G., & Manco, M. (2026) · Obesity and Endocrinology · doi:10.1093/obendo/wjag009
Junior, C. B., Blanco, G. G. R., Marcello, L. V., Rangel, G. T., Marques, N. D. C. D. S., Cinelli, L. P., & Cunha‐Júnior, E. F. (2026) · Drugs and Drug Candidates · doi:10.3390/ddc5020035
Pan, Y., Song, F., Liu, X., (8098), Y. Z., Zhang, J., Song, G., & Ren, L. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-04986-0
Altés, A., Moreno, Ó., Sastre-Belío, M., Rodríguez-Urgellés, E., Pérez-Alcántara, F., Larsen, S., Martín‐Lorenzo, A., Sandín, M., & Vidal, J. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03644-x
Clinical and economic aspects of semaglutide use in the treatment of obesity
Tibilova, A. L., Kozaeva, D. D., Aslakhanova, R. R., Tedety, V. Z., Tazurkaeva, M. Z., Gurtsieva, D. E., Kanteeva, E. E., Gabueva, M. S., Guatsaeva, V. I., Dzhigkaeva, A. M., et al. (2026) · FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology · doi:10.17749/2070-4909/farmakoekonomika.2026.369
Childhood Obesity: Epidemiology, Risk Factors, Prevention, and Emerging Treatment Strategies
Hadid, S. A., Frishman, W. H., & Aronow, W. S. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001359
GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists
Abid, M., Sheikh, K. S., Ahmad, M. S., & Jiang, H. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s566414
Rode, J. B., Wolf, J. M., Bolan, P. J., Palzer, E. F., Rudser, K. D., Aboobacker, S., Fox, C. K., Kelly, A. S., & Ryder, J. R. (2026) · Childhood Obesity · doi:10.1177/21532176261457202
Self-citationXu, Y., Yang, H., Xu, Q., Yu, X., Dai, S., Zhang, X., Shen, W., & Zhu, X. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00727-2
Buytaert, M., Vandekerckhove, K., Vangampelaere, M., Coomans, I., Lefere, S., Caen, K., Craemer, M. D., Gies, I., & Bruyne, R. D. (2026) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2026.115202
Self-citationChildhood Obesity and the Future Burden of Adult Cardiometabolic Disease: A Narrative Review
Balakrishna, H., Ajith, A., Sasi, S., & Sukumaran, S. M. (2026) · Cureus · doi:10.7759/cureus.111102
Pediatric Metabolic and Bariatric Surgery
Fleming, M. A., Morales, F. L., Inge, T. H., Reichard, K. W., & Michalsky, M. P. (2026) · Springer eBooks · doi:10.1007/978-3-032-24278-5_65
Bariatric surgery, depression, and sleep disturbances
Walędziak, M. S., & Różańska-Walędziak, A. M. (2026) · Polish Journal of Surgery · doi:10.5604/01.3001.0055.7958
The Risk of Retinal Vascular Events in Patients Using Semaglutide: A Scoping Review
Goudira, S. C., Højlund, K., & Grauslund, J. (2026) · Ophthalmologica · doi:10.1159/000553235
Access Barriers and Variable Response to Semaglutide in Severe Adolescent Obesity: A Case Series
Nguyen, A.-T., & Binkley, J. L. (2026) · Case Reports in Pediatrics · doi:10.1155/crpe/5562574
Alopecia secundaria a semaglutida
Pacheco, J. O., Monserrat-García, M. T., & García, E. G. (2026) · Medicina Clínica · doi:10.1016/j.medcli.2026.107507
GLP-1 Receptor Agonists in Adolescents: Emerging Endocrine, Reproductive, and Psychosocial Concerns
Haider, M. A., & Javed, H. (2026) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2026.06.017
Prediabetes in children and adolescents: what do we need to know?
Jang, K. M., & Zeitler, P. S. (2026) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2550222.111
Beyond Weight Loss: Early Real-World Evidence of Semaglutide in Obesity
Boroghină, S. C., Arhire, A. I., Papuc, T., Sinziana, C. M., Meluță, D.-A., Pîrcălabu, S. M., Dănăilă, R. A., Cristache, M., & Barbu, C. G. (2026) · Medicines · doi:10.3390/medicines13030021
Gueorguieva, I., Lespagnol, C., Saux, P., Järvholm, K., Stenberg, E., Aubry, E., Amsellem‐Jager, J., Coutant, R., Dabbas, M., Caiazzo, R. J., et al. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02134-y
Metadata
- Authors
- Weghuber, D., Barrett, T., Barrientos-Pérez, M., Gies, I., Hesse, D., Jeppesen, O. K., Kelly, A. S., Mastrandrea, L. D., Sørrig, R., & Arslanian, S.
- Affiliations
- University of Minnesota (US)
- From the Department of Pediatrics, Paracelsus Medical University, Salzburg, Austria (D.W.); the Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom (T.B.); the Division of Pediatric Endocrinology, Hospital Ángeles Puebla, Puebla City, Mexico (M.B.-P.); the Department of Pediatrics, Division of Pediatric Endocrinology, Universitair Ziekenhuis Brussel, Brussels (I.G.); Novo Nordisk, Søborg, Denmark (D.H., O.K.J., R.S.); the Department of Pediatrics and the Center for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis (A.S.K.); the Division of Pediatric Endocrinology and Diabetes, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY (L.D.M.); and the Center for Pediatric Research in Obesity and Metabolism, Division of Pediatric Endocrinology, Diabetes, and Metabolism, University of Pittsburgh School of Medicine, and UPMC Children’s Hospital of Pittsburgh, Pittsburgh (S.A.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-12-15
- Volume
- 387
- Issue
- 24
- Pages
- 2245-2257
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC9997064
- OpenAlex
- W4308053954
- Cited by
- 730
- References
- 26
- Citations by year
- 2026: 217 · 2025: 199 · 2024: 189 · 2023: 120 · 2022: 5
- FWCI
- 76.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion)
- PubMed Central (acceptedVersion)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- Digital Access to Libraries (submittedVersion, other-oa)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- semaglutide, adolescents, adolescent obesity, overweight, GLP-1 receptor agonists, weight loss, body mass index, cardiometabolic risk factors, lifestyle intervention, gastrointestinal adverse effects, gallstones, drug safety, weight-related comorbidities, HbA1c, alanine aminotransferase, waist circumference, serum lipids, serious adverse events
- MeSH terms
- Healthy Lifestyle, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Administration, Cutaneous, Adolescent, Child, Double-Blind Method, Humans, Weight Loss, Body Mass Index, Anti-Obesity Agents, Pediatric Obesity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
